We are analyzing https://link.springer.com/article/10.1186/s13046-018-0988-8.

Title:
Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors | Journal of Experimental & Clinical Cancer Research
Description:
Background Triple negative breast cancer (TNBC) is an aggressive neoplasia with no effective therapy. Our laboratory has developed a unique TNBC cell model presenting epithelial mesenchymal transition (EMT) a process known to be important for tumor progression and metastasis. There is increasing evidence showing that epigenetic mechanisms are involved in the activation of EMT. The objective of this study is to epigenetically reverse the process of EMT in TNBC by using DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi). Methods We evaluated the antitumor effect of three DNMTi and six HDACi using our TNBC cell model by MTT assay, migration and invasion assay, three dimensional culture, and colony formation assay. We then performed the combined treatment both in vitro and in vivo using the most potent DNMTi and HDACi, and tested the combined treatment in a panel of breast cancer cell lines. We investigated changes of EMT markers and potential signaling pathways associated with the antitumor effects. Results We showed that DNMTi and HDACi can reprogram highly aggressive TNBC cells that have undergone EMT to a less aggressive phenotype. SGI-110 and MS275 are superior to other seven compounds being tested. The combination of SGI with MS275 exerts a greater effect than single agent alone in inhibiting cell proliferation, motility, colony formation, and stemness of cancer cells. We also demonstrated that MS275 and the combination of SGI with MS275 exert in vivo antitumor effect. We revealed that the combined treatment synergistically reverses EMT through inhibiting EpCAM cleavage and WNT signaling, suppressing mutant p53, ZEB1, and EZH2, and inducing E-cadherin, apoptosis, as well as histone H3 tri-methylation. Conclusions Our study showed that DNMTi and HDACi exert antitumor activity in TNBC cells partially by epigenetically reprograming EMT. Our findings strongly suggest that TNBC is sensitive to epigenetic therapies. Therefore, we propose a new strategy to treat TNBC by using the combination of SGI-110 with MS275, which exerts superior antitumor effects by simultaneously targeting multiple pathways.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Science
Health & Fitness
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

cells, cell, cancer, sgi, treatment, pubmed, breast, article, emt, google, scholar, tnbc, combined, lines, cas, fig, hdaci, dnmti, epcam, growth, additional, expression, bsmcf, file, showed, ecadherin, assay, invasion, central, effect, compared, lmmcf, histone, tumor, ezh, treated, study, migration, significantly, combination, xtmcf, figure, transition, formation, signaling, studies, control, number, colony, hkme,

Topics {✒️}

beta-catenin-egr1-mediated pten expression triple-negative breast cancer twist/mi2/nurd protein complex epithelial-mesenchymal transition-related markers promotes epithelial-mesenchymal transition histone h3 tri-methylation reverses epithelial-mesenchymal transition article download pdf cdh1 promoter hyper-methylation formula ½lengthwidth2 figure 7a shows e-cadherin e-cadherin transcriptional downregulation tgf-beta induces global breast cancer negative ly-cor odyssey software cancer stem/progenitor cells real-time cell analyzer suppressing pi3k/akt signaling e-cadherin partially explained female cb17/scid mice cb17/scid mice showed histone deacetylase inhibitor epithelial mesenchymal transition epithelial-mesenchymal transition cb17/scid mice model bsmcf-luc cell line dna methyltransferase inhibitor cb17/scid mice started multiple anti-tumor effects anti-human vimentin antibody mir-130b-zeb1 axis n-terminal egf domain nod/scid mice started tgf beta-induced emt parental bsmcf-luc cells full size image attenuating mir-26a processing histone deacetylase inhibitors sin3a/histone deacetylase 1 dna methyltransferase inhibitors wnt/beta-catenin signaling unique cell model small lung cancer smooth outer surface e-cadherin gene expression breast epithelial cells significant anti-tumor effect important e-cadherin repressors growth factor receptor cell lines mda-mb-231

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors
         description:Triple negative breast cancer (TNBC) is an aggressive neoplasia with no effective therapy. Our laboratory has developed a unique TNBC cell model presenting epithelial mesenchymal transition (EMT) a process known to be important for tumor progression and metastasis. There is increasing evidence showing that epigenetic mechanisms are involved in the activation of EMT. The objective of this study is to epigenetically reverse the process of EMT in TNBC by using DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi). We evaluated the antitumor effect of three DNMTi and six HDACi using our TNBC cell model by MTT assay, migration and invasion assay, three dimensional culture, and colony formation assay. We then performed the combined treatment both in vitro and in vivo using the most potent DNMTi and HDACi, and tested the combined treatment in a panel of breast cancer cell lines. We investigated changes of EMT markers and potential signaling pathways associated with the antitumor effects. We showed that DNMTi and HDACi can reprogram highly aggressive TNBC cells that have undergone EMT to a less aggressive phenotype. SGI-110 and MS275 are superior to other seven compounds being tested. The combination of SGI with MS275 exerts a greater effect than single agent alone in inhibiting cell proliferation, motility, colony formation, and stemness of cancer cells. We also demonstrated that MS275 and the combination of SGI with MS275 exert in vivo antitumor effect. We revealed that the combined treatment synergistically reverses EMT through inhibiting EpCAM cleavage and WNT signaling, suppressing mutant p53, ZEB1, and EZH2, and inducing E-cadherin, apoptosis, as well as histone H3 tri-methylation. Our study showed that DNMTi and HDACi exert antitumor activity in TNBC cells partially by epigenetically reprograming EMT. Our findings strongly suggest that TNBC is sensitive to epigenetic therapies. Therefore, we propose a new strategy to treat TNBC by using the combination of SGI-110 with MS275, which exerts superior antitumor effects by simultaneously targeting multiple pathways.
         datePublished:2018-12-14T00:00:00Z
         dateModified:2018-12-14T00:00:00Z
         pageStart:1
         pageEnd:18
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s13046-018-0988-8
         keywords:
            Triple negative breast cancer
            Epithelial mesenchymal transition
            DNA methyltransferase
            Histone deacetylase
            Cancer Research
            Immunology
            Apoptosis
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-018-0988-8/MediaObjects/13046_2018_988_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-018-0988-8/MediaObjects/13046_2018_988_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-018-0988-8/MediaObjects/13046_2018_988_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-018-0988-8/MediaObjects/13046_2018_988_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-018-0988-8/MediaObjects/13046_2018_988_Fig5_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-018-0988-8/MediaObjects/13046_2018_988_Fig6_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-018-0988-8/MediaObjects/13046_2018_988_Fig7_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-018-0988-8/MediaObjects/13046_2018_988_Fig8_HTML.png
         isPartOf:
            name:Journal of Experimental & Clinical Cancer Research
            issn:
               1756-9966
            volumeNumber:37
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Yanrong Su
               url:http://orcid.org/0000-0002-7059-5930
               affiliation:
                     name:Fox Chase Cancer Center-Temple University Health System
                     address:
                        name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Nathan R. Hopfinger
               affiliation:
                     name:Fox Chase Cancer Center-Temple University Health System
                     address:
                        name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Theresa D. Nguyen
               affiliation:
                     name:Fox Chase Cancer Center-Temple University Health System
                     address:
                        name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Thomas J. Pogash
               affiliation:
                     name:Fox Chase Cancer Center-Temple University Health System
                     address:
                        name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Julia Santucci-Pereira
               affiliation:
                     name:Fox Chase Cancer Center-Temple University Health System
                     address:
                        name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Jose Russo
               affiliation:
                     name:Fox Chase Cancer Center-Temple University Health System
                     address:
                        name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors
      description:Triple negative breast cancer (TNBC) is an aggressive neoplasia with no effective therapy. Our laboratory has developed a unique TNBC cell model presenting epithelial mesenchymal transition (EMT) a process known to be important for tumor progression and metastasis. There is increasing evidence showing that epigenetic mechanisms are involved in the activation of EMT. The objective of this study is to epigenetically reverse the process of EMT in TNBC by using DNA methyltransferase inhibitors (DNMTi) and histone deacetylase inhibitors (HDACi). We evaluated the antitumor effect of three DNMTi and six HDACi using our TNBC cell model by MTT assay, migration and invasion assay, three dimensional culture, and colony formation assay. We then performed the combined treatment both in vitro and in vivo using the most potent DNMTi and HDACi, and tested the combined treatment in a panel of breast cancer cell lines. We investigated changes of EMT markers and potential signaling pathways associated with the antitumor effects. We showed that DNMTi and HDACi can reprogram highly aggressive TNBC cells that have undergone EMT to a less aggressive phenotype. SGI-110 and MS275 are superior to other seven compounds being tested. The combination of SGI with MS275 exerts a greater effect than single agent alone in inhibiting cell proliferation, motility, colony formation, and stemness of cancer cells. We also demonstrated that MS275 and the combination of SGI with MS275 exert in vivo antitumor effect. We revealed that the combined treatment synergistically reverses EMT through inhibiting EpCAM cleavage and WNT signaling, suppressing mutant p53, ZEB1, and EZH2, and inducing E-cadherin, apoptosis, as well as histone H3 tri-methylation. Our study showed that DNMTi and HDACi exert antitumor activity in TNBC cells partially by epigenetically reprograming EMT. Our findings strongly suggest that TNBC is sensitive to epigenetic therapies. Therefore, we propose a new strategy to treat TNBC by using the combination of SGI-110 with MS275, which exerts superior antitumor effects by simultaneously targeting multiple pathways.
      datePublished:2018-12-14T00:00:00Z
      dateModified:2018-12-14T00:00:00Z
      pageStart:1
      pageEnd:18
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s13046-018-0988-8
      keywords:
         Triple negative breast cancer
         Epithelial mesenchymal transition
         DNA methyltransferase
         Histone deacetylase
         Cancer Research
         Immunology
         Apoptosis
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-018-0988-8/MediaObjects/13046_2018_988_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-018-0988-8/MediaObjects/13046_2018_988_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-018-0988-8/MediaObjects/13046_2018_988_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-018-0988-8/MediaObjects/13046_2018_988_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-018-0988-8/MediaObjects/13046_2018_988_Fig5_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-018-0988-8/MediaObjects/13046_2018_988_Fig6_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-018-0988-8/MediaObjects/13046_2018_988_Fig7_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13046-018-0988-8/MediaObjects/13046_2018_988_Fig8_HTML.png
      isPartOf:
         name:Journal of Experimental & Clinical Cancer Research
         issn:
            1756-9966
         volumeNumber:37
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Yanrong Su
            url:http://orcid.org/0000-0002-7059-5930
            affiliation:
                  name:Fox Chase Cancer Center-Temple University Health System
                  address:
                     name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Nathan R. Hopfinger
            affiliation:
                  name:Fox Chase Cancer Center-Temple University Health System
                  address:
                     name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Theresa D. Nguyen
            affiliation:
                  name:Fox Chase Cancer Center-Temple University Health System
                  address:
                     name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Thomas J. Pogash
            affiliation:
                  name:Fox Chase Cancer Center-Temple University Health System
                  address:
                     name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Julia Santucci-Pereira
            affiliation:
                  name:Fox Chase Cancer Center-Temple University Health System
                  address:
                     name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Jose Russo
            affiliation:
                  name:Fox Chase Cancer Center-Temple University Health System
                  address:
                     name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal of Experimental & Clinical Cancer Research
      issn:
         1756-9966
      volumeNumber:37
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Fox Chase Cancer Center-Temple University Health System
      address:
         name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
         type:PostalAddress
      name:Fox Chase Cancer Center-Temple University Health System
      address:
         name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
         type:PostalAddress
      name:Fox Chase Cancer Center-Temple University Health System
      address:
         name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
         type:PostalAddress
      name:Fox Chase Cancer Center-Temple University Health System
      address:
         name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
         type:PostalAddress
      name:Fox Chase Cancer Center-Temple University Health System
      address:
         name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
         type:PostalAddress
      name:Fox Chase Cancer Center-Temple University Health System
      address:
         name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Yanrong Su
      url:http://orcid.org/0000-0002-7059-5930
      affiliation:
            name:Fox Chase Cancer Center-Temple University Health System
            address:
               name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Nathan R. Hopfinger
      affiliation:
            name:Fox Chase Cancer Center-Temple University Health System
            address:
               name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:Theresa D. Nguyen
      affiliation:
            name:Fox Chase Cancer Center-Temple University Health System
            address:
               name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:Thomas J. Pogash
      affiliation:
            name:Fox Chase Cancer Center-Temple University Health System
            address:
               name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:Julia Santucci-Pereira
      affiliation:
            name:Fox Chase Cancer Center-Temple University Health System
            address:
               name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
               type:PostalAddress
            type:Organization
      name:Jose Russo
      affiliation:
            name:Fox Chase Cancer Center-Temple University Health System
            address:
               name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
      name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
      name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
      name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
      name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA
      name:The Irma H. Russo, MD Breast Cancer Research Laboratory, Fox Chase Cancer Center-Temple University Health System, Philadelphia, USA

External Links {🔗}(258)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.61s.

LINK . SPRINGER . COM {}